Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06535607 · ClinicalTrials.gov registry record · Phase 2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
A Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
- 20
- Study locations
NCT06535607: Recruiting Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by AstraZeneca.
NCT06535607 is a Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 110 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06535607, a Phase 2 study of Cervical Cancer and Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
- 20
- Study locations
Study Summary
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
Primary Outcome
Confirmed ORR is defined as the proportion of participants who have a confirmed CR or confirmed PR, as determined by Investigator per RECIST 1.1.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Paclitaxel
- BIOLOGICAL Volrustomig
Study Locations (20)
Other
- Research Site - Ijuí
- Research Site - Londrina
- Research Site - São Caetano do Sul
- Research Site - Vitória
- Research Site - Beijing
- Research Site - Beijing
- Research Site - Beijing
- Research Site - Bengbu
- Research Site - Changchun
- Research Site - Changsha
- Research Site - Changsha
- Research Site - Changsha
- Research Site - Changsha
- Research Site - Chengdu
- Research Site - Chengdu
- Research Site - Chongqing
California
- Research Site - Los Angeles
Maryland
- Research Site - Baltimore
New York
- Research Site - Stony Brook
Ohio
- Research Site - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-08-22 |
| Est. Completion | 2028-11-30 |
| Phase | Phase 2 |
What NCT06535607 shows while recruiting
NCT06535607 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT06535607 names 20 study sites across 5 states, led by Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06535607 about?
NCT06535607 is a clinical study titled "Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors". eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
What is the current status of trial NCT06535607?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2024-08-22. Estimated completion is 2028-11-30.
What conditions does trial NCT06535607 study?
This clinical trial studies the following conditions: Cervical Cancer, Head and Neck Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06535607?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Paclitaxel (DRUG), Volrustomig (BIOLOGICAL).
Who is sponsoring clinical trial NCT06535607?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06535607 being conducted?
This trial has 20 study locations across California, Maryland, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06535607's enrollment target sits among peer trials
110 68th of 144 higher than 77 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI